Org 376845-HT2 agonist CAS# 213007-95-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 213007-95-5 | SDF | Download SDF |
PubChem ID | 9881884 | Appearance | Powder |
Formula | C14H20ClNO2 | M.Wt | 269.77 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 50 mM in water and to 100 mM in DMSO | ||
Chemical Name | (3S)-3-[(2,3--Dihydro-5-methoxy-1H- | ||
SMILES | COC1=C(C2=C(CCC2)C=C1)OC3CCNC3.Cl | ||
Standard InChIKey | KJEAKWPQCIAVGR-MERQFXBCSA-N | ||
Standard InChI | InChI=1S/C14H19NO2.ClH/c1-16-13-6-5-10-3-2-4-12(10)14(13)17-11-7-8-15-9-11;/h5-6,11,15H,2-4,7-9H2,1H3;1H/t11-;/m0./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Agonist of 5-HT2 receptors. Exhibits a rank order of potency of 5-HT2C >5-HT2B >5-HT2A (pEC50 values are 8.17, 7.96 and 7.11 respectively, in transfected CHO-K1 cells). |
Org 37684 Dilution Calculator
Org 37684 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.7069 mL | 18.5343 mL | 37.0686 mL | 74.1372 mL | 92.6715 mL |
5 mM | 0.7414 mL | 3.7069 mL | 7.4137 mL | 14.8274 mL | 18.5343 mL |
10 mM | 0.3707 mL | 1.8534 mL | 3.7069 mL | 7.4137 mL | 9.2672 mL |
50 mM | 0.0741 mL | 0.3707 mL | 0.7414 mL | 1.4827 mL | 1.8534 mL |
100 mM | 0.0371 mL | 0.1853 mL | 0.3707 mL | 0.7414 mL | 0.9267 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Boc-Tyr(Bzl)-OH
Catalog No.:BCC3461
CAS No.:2130-96-3
- Tetrahymanol acetate
Catalog No.:BCN6933
CAS No.:2130-22-5
- Tetrahymanol
Catalog No.:BCN6934
CAS No.:2130-17-8
- (S)-(+)-Abscisic acid
Catalog No.:BCN2210
CAS No.:21293-29-8
- Purvalanol B
Catalog No.:BCC3887
CAS No.:212844-54-7
- Purvalanol A
Catalog No.:BCC5654
CAS No.:212844-53-6
- Cowaxanthone B
Catalog No.:BCN3892
CAS No.:212842-64-3
- Kumokirine
Catalog No.:BCN2011
CAS No.:21284-20-8
- Kuramerine
Catalog No.:BCN1806
CAS No.:21284-19-5
- Ramage Linker,Fmoc-Suberol
Catalog No.:BCC2834
CAS No.:212783-75-0
- NG 52
Catalog No.:BCC1798
CAS No.:212779-48-1
- Xanthiazone
Catalog No.:BCN2544
CAS No.:212701-97-8
- Ceanothic acid
Catalog No.:BCN4918
CAS No.:21302-79-4
- [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2
Catalog No.:BCC5701
CAS No.:213130-17-7
- RITA (NSC 652287)
Catalog No.:BCC2238
CAS No.:213261-59-7
- H-Pro-OMe.HCl
Catalog No.:BCC3022
CAS No.:2133-40-6
- 15,18-Dihydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1495
CAS No.:213329-45-4
- 18-Nor-4,15-dihydroxyabieta-8,11,13-trien-7-one
Catalog No.:BCN1494
CAS No.:213329-46-5
- 1-Methyl-L-tryptophan
Catalog No.:BCN8341
CAS No.:21339-55-9
- Ercalcidiol
Catalog No.:BCC1555
CAS No.:21343-40-8
- Flumethasone
Catalog No.:BCC8986
CAS No.:2135-17-3
- Drim-7-ene-11,12-diol acetonide
Catalog No.:BCN4919
CAS No.:213552-47-7
- 5-Iodo-A-85380, 5-trimethylstannyl N-BOC derivative
Catalog No.:BCC7102
CAS No.:213766-21-3
- 6,8-Cyclo-1,4-eudesmanediol
Catalog No.:BCN4920
CAS No.:213769-80-3
Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat.[Pubmed:11999893]
Prog Neuropsychopharmacol Biol Psychiatry. 2002 Apr;26(3):441-9.
Compounds that stimulate 5-HT2C and/or 5-HT1B receptors induce hypophagia, but the relative role of these receptors in the control of feeding behaviour remains to be unequivocally demonstrated. The objectives of the present study were: (a) comparison of the hypophagic effect of the mixed 5-HT2C/1B receptor agonist, m-CPP, with that of Org 37684 and CP-94,253, a relatively selective 5-HT2C and 5-HT1B receptor agonist, respectively; (b) verification of the contribution of 5-HT2C receptors to the hypophagic effect of these compounds by antagonism experiments; and (c) to test whether cotreatment with Org 37684 and CP-94,253 leads to a more pronounced reduction of food intake as compared with treatment with either compound alone. Food intake was measured in a free feeding experimental protocol employing female Wistar rats. m-CPP was more potent in suppressing food intake than Org 37684 and CP-94,253 (ED50 values for the first hour of access: 0.45, 1.84 and 3.48 mg/kg ip, respectively). The 5-HT2C receptor antagonists, metergoline and SB 242.084, completely reversed the hypophagic effect of Org 37684, but not that of CP-94,253 and m-CPP. The hypophagic effect of Org 37684 was potentiated by a low (inactive) dose of CP-94,253 (ED50: 4.95 and 2.44 mg/kg ip after vehicle and CP-94,253 pretreatment, respectively) and vice versa (ED50 values: 4.02 and 0.62 mg/kg ip). It is concluded that the hypophagic effect of Org 37684-but not that of m-CPP and CP-94,253--is exclusively mediated by activation of 5-HT2C receptors. The results further indicate that simultaneous activation of 5-HT2C and 5-HT1B receptors underlies the higher potency of m-CPP in reducing food intake, as compared with other, more selective, compounds.
Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action.[Pubmed:10781694]
Neurosci Biobehav Rev. 2000 May;24(3):341-53.
Serotonin (5-HT) receptor agonists with high affinity for the different subtypes (i.e. 5-HT(1A-1F), 5-HT(2A-2C)) of the 5-HT(1)- and 5-HT(2) receptor families have been shown to affect ingestive behavior. It has been assumed that: (1) stimulation of hypothalamic 5-HT(2C) or 5-HT(1B) receptors leads to a behaviorally specific hypophagic effect by accelerating satiety processes; (2) stimulation of 5-HT(2A) receptors leads to a disruption of the feeding cascade; and (3) stimulation of 5-HT(1A) and 5-HT(2B) receptors leads to a hyperphagic effect. The present paper reviews studies performed with the relatively selective receptor agonists ipsapirone (5-HT(1A)), CP-94,253 (5-HT(1B)), BW 723C86 (5-HT(2B)) and Org 37684 (5-HT(2C)), as well as the nonselective receptor agonists TFMPP (5-HT(1B/2C)), m-CPP (5-HT(2C/1B)) and DOI (5-HT(2A/2C)) in a variety of feeding paradigms in rats, both after systemic and local injection. These studies support a role for other neuroanatomical regions (i.e. brain stem) and behavioral mechanisms (i.e. appetitive processes) in the hypophagic effects of these compounds, possibly as a function of the administered dose. Studies with 5-HT receptor antagonists indicate that the proposed role of particular 5-HT(1/2) receptor subtypes in the hypophagic effects of these 5-HT receptor agonists may be more complicated than originally thought. Further characterization of the role of 5-HT(1/2) receptor subtypes in the control of ingestive behavior will require extensive pharmacological and behavioral studies, using more selective receptor agonists and antagonists and different behavioral procedures, as well as verification in transgenic animals.
Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells.[Pubmed:10498829]
Br J Pharmacol. 1999 Sep;128(1):13-20.
1. The goal of this study was to characterize the agonist pharmacology of human 5-HT2A, 5-HT2B and 5-HT2C (VSV) receptors expressed in CHO-K1 (Chinese hamster ovary) cells. 2. We used a fluorometric imaging plate reader (FLIPR) which allows rapid detection of rises in intracellular calcium levels upon the addition of agonists. 3. Stimulation of all three receptors by 5-HT caused a robust concentration dependent increase in intracellular calcium levels. No such effect was observed from non-transfected control CHO-K1 cells. 4. The rank order of potency of agonists at the different receptor subtypes varied. Tryptamines, BW-723C86, d-norfenfluramine, Ro 60-0175 and LSD exhibited the following rank order of potency; 5-HT2B>5-HT2C>5-HT2A. Piperazines such as m-Chlorophenylpiperazine (mCPP), ORG-12962, MK-212 and also ORG-37684 exhibited a rank order of potency of 5-HT2C>5-HT2B>5-HT2A. The phenylisopropylamines DOI and DOB had a rank order of 5-HT2A>5-HT2B>5-HT2C. 5. Many agonists tested had partial agonist actions when compared to 5-HT, and a wide range of relative efficacies were exhibited, which was cell line dependent. For example, mCPP had a relative efficacy of 65% at 5-HT2C receptors but <25% at either 5-HT2A or 5-HT2B receptors. 6. Interpretation of literature values of functional assays using different cell lines, different receptor expression levels and different receptor isoforms, is complex. Species differences and the previous use of antagonist radioligands to characterize agonist potency in binding assays emphasizes the importance of studying agonists in the same experiment using the same assay conditions and parental cell lines.